By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today said that it has entered into a long-term cancer drug screening pact with Japanese pharmaceutical firm Daiichi Sankyo.

Martinsried, Germany-based Kinaxo said that Daiichi Sankyo will use its chemical proteomics technologies Cellular Target Profiling and KinAffinity, as well as its phosphoproteomics technology PhosphoScout in various research programs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.